Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

The use of pdl1 SNP genotype as a marker for predicting the efficacy of neoadjuvant chemotherapy in breast cancer

A genotype, breast cancer technology, applied in the field of medical detection, can solve problems such as unsatisfactory pCR rate, and achieve the effect of avoiding excessive treatment, improving survival time, and delaying the timing of surgery.

Active Publication Date: 2021-07-23
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in hormone receptor (Hormone receptor, HR) positive patients, the pCR rate is not ideal, so we hope to find predictors of pCR in this part of patients, so as to improve the treatment effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The use of pdl1 SNP genotype as a marker for predicting the efficacy of neoadjuvant chemotherapy in breast cancer
  • The use of pdl1 SNP genotype as a marker for predicting the efficacy of neoadjuvant chemotherapy in breast cancer
  • The use of pdl1 SNP genotype as a marker for predicting the efficacy of neoadjuvant chemotherapy in breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] In order to clarify the predictive effect of the SNP genotype in the non-coding region of the PDL1 gene (as shown in SEQ ID NO.1) on the sensitivity of breast cancer neoadjuvant chemotherapy, especially in order to clarify its predictive effect in HR-positive breast cancer; at the same time, observe Tolerance and safety of treatment in patients with different genotypes. We hypothesized that in all populations as well as in HR-positive breast cancer, the PDL1 SNP genotype could predict patient sensitivity and tolerance to treatment, and performed sensitivity analysis by detecting the SNP genotype in whole blood samples of patients before neoadjuvant chemotherapy .

[0021] 1 Materials and methods

[0022] 1.1 Main Instruments

[0023]

[0024] 1.2 Main kit consumables

[0025]

[0026] 1.3 Enrolled patients and sample collection

[0027] All the selected cases come from the patients enrolled in two clinical trials of the Breast Surgery Department of Renji Hospi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides the use of the PDL1 SNP genotype in the preparation of markers for diagnosis and prediction of the curative effect of neoadjuvant chemotherapy for breast cancer. Also provided is the use of the PDL1 SNP genotype as a marker in the preparation of reagents for diagnosing and predicting the curative effect of neoadjuvant chemotherapy for breast cancer. Also provided is a kit for detecting the PDL1 SNP genotype, which contains the primers shown in SEQ ID NO.1-18. The present invention finds that in all breast cancer populations and HR-positive populations, after the SNP rs4143815 C to G change in the non-coding region of PDL1 gene, patients with GC genotype are more likely to achieve pCR than patients with GG and CC genotypes. Through the detection of the SNP in the non-coding region of the PDL1 gene in the patient's blood, patients with the GC genotype can be detected as early as possible, and neoadjuvant chemotherapy can be performed in order to achieve complete remission of the pathology and improve the survival time.

Description

technical field [0001] The invention belongs to the field of medical detection, and relates to a marker for predicting the curative effect of neoadjuvant chemotherapy for breast cancer, specifically the use of PDL1 SNP genotype as a marker for predicting the curative effect of neoadjuvant chemotherapy for breast cancer. Background technique [0002] Breast cancer is one of the most common malignancies in women worldwide. According to the latest global cancer epidemiological statistics (GLOBOCAN) report, in 2012 alone, there were 1.67 million new cases of breast cancer worldwide, and 522,000 people died of breast cancer. In the same year, the age-standardized incidence rate of breast cancer in China reached 21.6 per 100,000 people. Although the incidence of breast cancer in China is still lower than that of developed countries (as high as 100 per 100,000 people in North America and Northern Europe), it has been on the rise since the 1980s, and the growth rate is more than tw...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886C12N15/11
CPCC12Q1/6886C12Q2600/106C12Q2600/156
Inventor 陆劲松张蕾徐曙光吴子平
Owner RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com